Tigulixostat (IBI128) vs Febuxostat in Gout

Summary

The primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level \< 360 μmol/L at Week 24. The study also evaluates safety, gout attacks, kidney function, inflammation, and quality of life over 52 weeks of treatment. Approximately 600 eligible participants will be randomized to receive either Tigulixostat or Febuxostat.

Timeline

Start

2026-03-17

Primary completion

2027-04-30

Completion

2027-10-30

Drugs

Indications